POLYPEPTIDES HAVING SERINE PROTEASE INHIBITOR ACTIVITY AND DNA CODING THEREFOR

Abstract: A serine protease inhibitor, similar in some respects to alpha 1-antitrypsin (AAT) but having an unglycosylated molecular weight on PAGE of 32+/-1 kDa, has been discovered. cDNA encoding the active protein has been cloned and sequenced, so the sequence of the protein has been revealed. Recombinant DNA technology enables the natural polypeptide sequence and related proteins to be prepared, for example by expression in E. coli. The inhibitor may prove useful in the treatment of emphysema, arthritis or septic shock.

Description: Poiypeptides having serine protease inhibitor activity and DNA coding therefor This invention relates to poiypeptides, especially poiypeptides having activity of the serine-protease inhibitor type, to DNA encoding therefor and to pharmaceutical preparations containing the inhibitor. Proteolytic enzymes released during the inflammatory process, by neutrophils in particular, are thought to play a central role in tissue damage associated with chronic lung diseases such as pulmonary emphysema and bronchiectasis (Janoff A (1985) Am Rev Resp Pis 132, 417) . Most individuals remain relatively healthy with minimal tissue damage following an inflammatory response because the blood and lung tissues contain several inhibitors to counteract the effects of proteinases (Stoc ley R (1983) Clin Sci 64, 119). α- ^ -antitrypsin (AAT) is a major inhibitor of serine proteinases present in the blood and in lung secretions. Its major physiological function is to protect the lower respiratory tract from neutrophil elastase, an enzyme implicated in the damage of lung connective tissue that occurs in chronic lung disease (Carell R , Jeppsson JO, Laurell CB et al. (1982) Nature 298, 329) . Individuals with inherited deficiency of AAT are predisposed to developing early onset adult pulmonary emphysema particularly if they smoke (Laurell CB, Eriksson S. (1963) Scand J Clin Lab Invest IS, 132). Although other serine proteinase-inhibitors probably also play a role in protecting the lung from proteolytic degradation, these have either been poorly characterised or genetic abnormalities of these inhibitors have yet to be described in association with chronic lung disease. It seems likely that other genetic factors contribute to chronic lung disease. Of potential relevance are abnormalities in related proteins. Previous reports suggested that there may be immunologically cross-reacting material detected by antibodies to α j -antitrypsin (Glew RH, Zidian JL, Chiao JP et al (1981) In: "Electrophoresis", Walter de Gruyter, page 5115; Mittman C, Teevee B, Lieber an J (1973) J Occ Med 15, 33) and three related genes have been detected in a rat liver cDNA library (Krauter KS, Citron BA, Hsu MT (1986) DNA 5, 29) suggesting that other putative serine proteinase-inhibitors remain to be characterised. Less than 5% of all patients who develop pulmonary emphysema have a clearly identifiable abnormality of AAT protein (Mittman C, Teevee B, Lieberman J (1973) J Occ Med 15, 33) and only about 10-20% of cigarette smokers are particularly vulnerable to the onset of pulmonary emphysema (Niewhoner DE (1983) In: "Textbook of Pulmonary Diseases" page 915) . A polymorphism of the AAT gene that occurs in about 20% of patients with pulmonary emphysema has recently been described (Kalsheker NA, Hodgson IJ, Watkins GL et al. (1986) Am Rev Resp Pis 133, A219) . This polymorphism may be linked to other candidate genes involved in the pathogenesis of chronic lung disease. It is now known that in humans two other potentially important genes occur within 100 kilobase pairs (kb) to AAT on chromosome 14. These are α- ^ -antichymotrypsin (ACT) (Rabin M, Watson M, Kidd V et al. (1986) Somat Cel Mol Genet 12, 209) and an AAT gene-related sequence (ASRG) (Lai E, Kao F, Law M et al. (1983) Am J Hum Genet 35, 385) which may code for a serine proteinase-inhibitor with an anti-elastase activity (according to Professor S. Woo, Baylor Medical School, Houston, Texas) . The isolation of several AAT cDNA clones from a human liver cDNA library has previously been reported (Kalsheker N, Chiswell P, Markha A et al (1985) Ann Clin Bioche 22, 25). Although an understanding of the structure and role of AAT is clearly of major significance in the diagnosis and potential management of pulmonary emphysema, it is clear that AAT is unlikely to provide a complete answer. A problem facing workers in the field is to identify further serine protease inhibitors, not least so that they can be studied to develop further understanding of disease such as pulmonary emphysema. Nucleic acid having significant nucleotide sequence differences from PNA coding for AAT and ACT has now been isolated and cloned. Protein corresponding to the sequence has been made by the use of a suitable host/vector system and has displayed serine protease inhibitory activity. A new human serine protease inhibitor has therefore been discovered and prepared. According to a first aspect of the invention, there is provided a human serine protease inhibitor whose unglycosylated molecular weight is 32 kDa + 1 kDa. The molecular weight may be measured (for example by polyacrylamide gel electrophoresis (PAGE) ) under conditions in which one or more of the following marker proteins have the molecular weights shown: α-lactalbumin 14.4 kDa soybean trypsin inhibitor 20.1 kPa carbonic anhydrase 30 kDa ovalbumin 43 kDa bovine serum albumin 67 kDa As will be described below, the thermal stability and pH stability characteristics of the serine protease inhibitor of this aspect of the invention may constitute additional distinctions from AAT. The present invention provides in a second aspect a proteinaceous molecule selected from: (a) a molecule having the amino acid sequence shown in SEQ ID NO:l or a sequence not differing substantially therefrom; b) a polypeptide having substantially the same structure and biological activity as a) ; and c) fragments, derivatives and mutants of a) or b) significantly involved in their biological activity. The sequence from Leu 38 is identical to the terminal sequence of AAT suggesting that this sequence - is significant for activity. Conversely, residues 1 to 37 serve to distinguish proteins of this invention from AAT. Among the fragments within the scope of the present invention are those start at internal methionine residues. Such poiypeptides differ from AAT in having shorter sequence of different composition at the N-terminal end which it is believed from tertiary structure predictions would result in the loss of alpha-helical structure. Accordingly the present invention provides in a third aspect a proteinaceous molecule selected from: (a) a polypeptide having serine protease inhibitor activity and whose amino terminus includes the sequence of amino acids 1 to 37 of SEQ ID NO: 1 or a sequence not differing substantially therefrom; b) a polypeptide having substantially the same structure and biological activity as a) ; c) fragments, derivatives and mutants of a) or b) significantly involved in their biological activity. It will be understood by those skilled in the art that some variation in structure may occur in naturally occurring biologically active poiypeptides but , provided that such structural variations do not eliminate biological activity of interest, for example serine protease inhibition , the present invention includes such variations within its scope. One form of variation may be to have one or more additional N-terminal amino acid residues. It is difficult to put precise limits on the variation in amino acid residues which may be tolerated since, as will be understood by those skilled in the art, some regions and some residues are more significant than others. Conserved regions which play an important role in biological activity are likely to be less tolerant of variation and another aspect of the present invention provides poiypeptides containing or consisting of one or more conserved sequences. By "conserved" we mean having significant sequence homology with other proteins of interest. It is not possible to put precise numerical limits on the degree of homology but 25% can be significant and 80% or greater, say, would in many examples be expected to be highly significant, depending upon where the homology occurs, amongst other factors. Derivatives of the polypeptide of the invention are, for example, where functional groups, such as amino, hydroxyl, mercapto or carboxyl groups, are derivatised, e.g. glycosylated, acylated, amidated or esterified, respectively. In glycosylated derivatives an oligosaccharide is usually linked to asparagine, serine, threonine and/or lysine. Acylated derivatives are especially acylated by a naturally occurring organic or inorganic acid, e.g. acetic acid, phosphoric acid or sulphuric acid, which usually takes place at the N-terminal amino group, or at hydroxy groups. especially of tyrosine or serine, respectively. Esters are preferably those of naturally occurring alcohols, e.g. methanol or ethanol. Glycosylation may take place on any suitable residue; asparagine residues are particularly suitable for glycosylation, especially when they are in exposed sites on the tertiary structure. Glycosylation at sites corresponding to the natural sites of glycosylation of AAT may be preferred, at least in the common portion of the sequence. It appears that glycosylation is not essential for biological activity. Further derivatives are salts, especially pharmaceutically acceptable salts, such as alkali metal and alkaline earth metal salts, e.g. sodium, potassium, magnesium, calcium or zinc salts, or ammonium salts formed with ammonia or a suitable organic amine, such as a lower alkylamine, e.g. triethylamine, hydroxy-lower alkylamine, e.g. 2-hydroxyethylamine and the like. Mutants of the poiypeptides of the invention are characterised in the exchange of one (point mutant) or more, about up to 10, of its amino acids against one or more of another amino acid. They are the consequence of the corresponding mutations at the DNA level leading to different codons. Natural and synthetic mutants are included within the scope of the invention. Further variations which may be acceptable include for example, fusion proteins, conservative mutants, allelic variation, polymorphisms, oligomeric forms and the like, provided these do not affect essential features of composition, structure or activity to an unacceptable degree. Proteinaceous molecules in accordance with the invention may be prepared or, if natural, isolated by any suitable means. Synthesis will generally be preferred even for natural molecules, although semi-synthetic preparations may be more appropriate under some circumstances. According to a further aspect of the invention, there is provided a process for the preparation of a proteinaceous molecule as described above, the process comprising coupling together successive amino acid residues and/or ligating oligo- and/or poiypeptides. Glycosylation or other modification may take place at any suitable stage, if desired. Although proteinaceous molecules in accordance with the invention of the present invention may be prepared by chemical synthesis, where the number of amino acid residues is not too large, it is preferred to prepare them by translation of RNA. While __n vitro RNA translation systems may be appropriate under some circumstances, DNA expression will generally be the method of choice. According to a further aspect of the invention, there is therefore provided recombinant or isolated DNA encoding a proteinaceous molecule as described above. Preferred DNA in accordance with the invention codes for the amino acid sequence shown in SEQ ID N0:1 or for a polypeptide having serine protease inhibitor activity and whose amino terminus includes the sequence of amino acids 1 to 37 of SEQ ID NO: 1 or a sequence not differing substantially therefrom. It will be appreciated that although the nucleotide sequence shown in SEQ ID N0:1 may itself be preferred for expression, the degeneracy of the genetic code means that many nucleotide sequences can code for a given amino acid sequence. DNA in accordance with the invention may consist essentially of DNA as described above or may additionally include other sequences. Fragments, derivatives and mutants of proteinaceous molecules of the invention may be encoded by DNA which is similar to DNA encoding at least part of the amino acid sequence shown in SEQ IP NO:l. Similarity may be gauged by hybridisation experiments. DNA which hybridises, for example under stringent conditions, to at least part of the DNA sequence shown in SEQ ID NO:l, or to another DNA sequence encoding at least part of the amino acid sequence shown in SEQ ID NO:l forms part of the invention. Stringent conditions are exemplified by 35-65"C at a salt concentration of about 0.9 molar. Recombinant DNA in accordance with the invention may be in the form of a vector. The vector may for example be a plasmid, cosmid or phage or other virus. Vectors will frequently include one or more selectable markers to. enable selection of cells transfected (or transformed: the terms are used interchangeably in this specification) with them and, preferably, to enable selection of cells harbouring vectors incorporating heterologous DNA. Appropriate start and stop signals will generally be present. Additionally, if the vector is intended for expression, sufficient regulatory sequences to drive expression will be present. Vectors not including regulatory sequences are useful as cloning vectors. Suitable vectors include the plas id pKK 233-serpin. Cloning vectors can be introduced into E. coli or another suitable host which facilitate their manipulation. Suitable hosts include a K12 strain of E. coli JM105. As glycosylation does not appear to be essential for biological activity, expression may take place in prokaryotes or eukaryotes. E. coli will usually be the prokaryotic organism of choice. As for eukaryotes, although yeasts such as Saccharomvces cerevisiae may be suitable, the different glycosylation patterns of yeasts may mean that other eukaryotic expression hosts are preferred. Insect cells, such as those transfected with Baculovirus, may be used as may mammalian cells such as COS cells, which could for example be SV40-transfected. According to another aspect of the invention, there is therefore provided a host cell transfected or transformed with DNA as described above. DNA in accordance with the invention can be prepared by any convenient method involving coupling together successive nucleotides, and/or ligating oligo- and/or poly-nucleotides, including .in vitro processes, but recombinant DNA technology forms the method of choice. DNA of the present invention may be recovered from cDNA libraries by methods known in the art and it will .be understood that, once the nucleotide sequence is known, direct amplification is possible by the poly erase chain reaction, for example. (Saiki et al, Science (1985) 230 1350-1354) . Recombinant DNA sequences in accordance with the invention can be prepared entirely from using publicly and commercially available materials. For example, a human liver cDNA library can be used, such as the Derek Woods Library (Children's Hospital, 300 Longwood Ave, Boston, MA 02115, U.S.A.). Alternatively, cDNA can be prepared from total human RNA using reverse transcriptase. CG tails can be added to cDNA by the homopolymeric tailing techniques The resulting tailed cDNA can be screened with an α-^-antitrypsin probe (which may be synthetic or a fragment of or the whole natural sequence) , which enables identification of putative positive clones. A PstI fragment can then be isolated, by virtue of the CG tailing. The PNA of the present invention may also be useful for diagnostic, screening, or other purposes. From the cDNA sequence of SEQ ID NO:l, it has been established that there are regions of unique DNA sequence corresponding to regions of unique amino acid sequence. The sequence of 5 amino acid residues is considered sufficient to confer a greater than 90% probability of uniqueness for a protein. One or more short unique stretches may. be used to synthesise chemically unique peptides - this service is available commercially - to raise specific antibodies. Specific polyclonal antibodies may be tested for reactivity to human serum and to liver homogenate to investigate if the protein is present in both tissues using antibodies that do not react with AAT or ACT. Proteinaceous molecules of the present invention may be useful for example, in the treatment of conditions associated with deficiency of serine protease inhibitors. They may thus display leukocyte elastase inhibitor, cathepsin G inhibitor, trypsin inhibitor and/or pancreatic elastase inhibitor activities, suggesting utility in the treatment of such conditions as emphysema, arthritis or septic shock. In a further aspect, the invention therefore provides a proteinaceous molecule as described above for use in medicine. The invention also provides the use of a proteinaceous compound as described above in the manufacture of a medicament for the treatment or prophylaxis of emphysema, arthritis or septic shock. The invention also provides a method for the treatment or prophylaxis of emphysema, arthritis or septic shock, the method comprising administering to a patient an effective, generally non-toxic, amount of a proteinaceous compound as described above. The invention further provides pharmaceutical preparations containing as an active ingredient one or more proteinaceous compounds as described above. Such preparations may be formulated with suitably acceptable carriers for administration as inhalants or parenterally, for example. Preparations adapted for parenteral administration will usually be sterile. Heat stability tests indicate that the poiypeptides of the present invention may be more stable to heat treatment (for example at 60 β C for 30 minutes) than human serum and/or than AAT; however, the pH stability appears to be less than that of AAT (for example at pH <4.5 proteins of the invention may at least in some circumstances be inactivated, whereas some (such as about 30%) activity may be retained by AAT, and at pH >9 proteins of the invention may be inactivated. The present invention also provides antibodies to the proteinaceous molecules of the invention. They may be made by techniques known in the art (see for example: "Antibodies, A Laboratory Manual", E. Harlow and D. Lane, Cold Spring Harbor, 1988) and may include polyclonal and monoclonal antibodies which may be useful inter alia for diagnostic purposes, e.g. in diagnosis of deficiency states. Should abnormalities associated with predisposition to disease be identified, such information could provide a potential risk assessment. Specific embodiments of the invention will now be described by way of example only and with reference to the sequences shown in SEQ ID NO:l, which shows the sequence of amino acid residues for a preferred polypeptide of the present invention and DNA sequence (as a BamHI/Hindlll fragment) encoding it. πYΑMPT.Ε ι - Isolation and Sequencing A cDNA library was prepared from human liver poly A+ messenger RNA and cloned into the PvuII site of the plasmid vector pAT153 which had BamHI and Hindlll linkers attached. The library consisted of 100,000 individual recombinants. Five thousand independent colonies were screened using a radioactively labelled 1350 base pair (bp) DNA probe corresponding to the coding sequence of the AAT gene. After repeated screening a clone was isolated which contained restriction fragments that were different to what was expected. It contained an unusually large BamHI/ Hindlll fragment on digestion with both restriction enzymes. The predicted size of the BamHI/Hindi11, for AAT, should have been about 130 bp but the actual fragment was found to be about 350 bp. A sample of the cloned cell-line, under the description E. coli K12 strain, HBlOl-clone A5 (plasmid pAT153) , was deposited at the NCIMB, Torrey Research Station, PO Box 31, 135 Abbey Road, Aberdeen, United Kingdom, AB9 8DG on 15th December, 1989 with Accession Number 40237. The BamHI/Hindlll fragment was cloned into M13 (mpl8 and mpl9) for sequencing and contained sequence which was different from that for AAT. The sequence corresponded to untranslated regions at the 3'end of the cDNA clone. The DNA sequence of SEQ ID NO:l also contains two intermediate BamHI restriction site at nucleotide positions l to 6 and 991 to 996. The 1000b BamHI/BamHI fragment was sequenced and this also contained significantly different sequence at the 5' end. Using the nomenclature of Long et a_L. , Biochemistry 1984, 23, 4828, for AAT, the bases from 126 to 15 were inverted, 127-486 were missing and the remainder of the sequence was identical to AAT including the active site. The nucleotide and corresponding amino acid residue sequences are represented in SEQ ID NO:l; the coding region runs from nucleotide residue 3 (a first isoleucine) to 929 (a stop codon) . It will be noted that the BamHI sites are at positions 1 to 6 and 991 to 996, respectively. EXAMPLE 2 - Expression of pKK233-2 A BamHI fragment, containing the first exon of AAT in reverse orientation, and sequence from base 487 to 1380 (using the numbering system of Long et al..) in the same orientation as AAT was cloned into the plasmid expression vector pKK233-2 in a reading frame that would correspond to AAT. The cloning was achieved by filling in the ends of BamHI fragment, ligating an 8 base linker (GCCATGGC) containing a recognition site for the restriction enzyme Ncol (CCATGG) , cutting with Ncol and cloning the fragment into the Ncol site of the vector pKK 233-2. This fragment if in the correct orientation would result in the expression of an unfused protein in E. coli in the same orientation as AAT. A K12 strain of E. coli. JM105, was used as a host cell and a sample of the transformed cell line, under the description E. coli, K12 strain JM105-clone pKK233-serp (plasmid pKK-2) , was deposited at the NCIMB, Torrey Research Station, PO Box 31, 135 Abbey Road, Aberdeen, United Kingdom, AB9 8DG, on 21st December, 1989 with Accession Number 40244. Transformed cells were expressed by growing them up to an optical density of 0.3 and then adding 10 mM IPTG (isopropylthiogalactoside) , an inducer of the β-galactosidase gene, which is placed in front of the cloned gene fragment and growing cells for 5 hr at 37°C. The foreign protein expressed had a molecular weight of 32 kDa ± 1 kDa on PAGE under conditions in which one or more of the following marker proteins have the molecular weights shown: α-lactalbumin 14.4 kDa soybean trypsin inhibitor 20.1 kDa carbonic anhydrase 30 kDa ovalbumin 43 kDa. bovine serum albumin 67 kDa. EXAMPLE 3 - Expression of pNHlδa The BamHI fragment extending from nucleotide position 1 to 996 (Example 1) was cloned into the BamHI site of the expression vector pNH18a. A sample of the cloned cell line, under the description E. coli K12 strain D1210HP (plasmid pNH18a) was deposited at the NCIMB, Torrey Research Station, PO Box 31, 135 Abbey Road, Aberdeen AB9 8DG, United Kingdom on 5th December 1990 under Accession No. NCIMB 40341. pNH is a vector that contains two invertible promoters in tandem. Expression of inserts is regulated by heat-induced inversion of the prokaryotic promoters. Inversion is accomplished by site-specific recombination which is mediated by the phage Int product of the E. coli host strain D1210 HP and attB and attP recognition sequences of the plasmid. A heat-pulse switches the promoter from the "OFF" to the "ON" position and the Int-mediated conversion is 95% efficient. The details of induction and expression are as follows. Bacterial (D1210HP) were grown to an optical density of 0.3 (measured at 600nm) in 250ml of LB-broth. The cells were heat-pulsed at 42°C for 2 minutes and IPTG was added to a final concentration of ImM. The cells were grown overnight at 37*C and then centrifuged at 500g for 15 minutes at 4 β C. The cells were resuspended in 3ml of lysis buffer (50mM Tris-HCl-pH 8.0, ImM EDTA, lOOmM NaCl)/g of cells. Phenylmethylsulphonylfluoride (PMSF) (8μl/g) , lysozyme (lO g/ml) and deoxycholic acid (4mg/g) were added. The mixture was placed in a 37 ° C waterbath, stirred and then incubated with 20μl of DNAasel (lmg/ml)/g of cells till the mixture was no longer viscous. The cell lysate was centrifuged at 12000g for 15 minutes at 4 β C. The pellet was resuspended in O.lmM PMSF and 8M urea and left for 1 hour at room temperature. This solution was treated with 9 volumes of 50mM KH 2 P0 4 (pH 10.7), ImM EDTA (pH 8.0) and 50mM NaCl for 30 minutes. the pH was then adjusted to 8.0 with HC1. The mixture was centrifuged at 12000g for 15 minutes at room temperature and the pellet was resuspended for further analysis. EXAMPLE 4 - Activity of protein expressed from pKK233-2 Cells from Example 2 were pelleted, washed in physiological saline and after two cycles of osmotic lysis followed by freeze/thawing the supernatants were analysed for biological and immunological activity. From a 5ml culture approximately 400 μl of supernatant was collected and by immunochemical measurements with antibodies to human alphal-antitrypsin approximately 1.4 μg of protein was obtained. Using an assay for the inhibition of elastase 15 μl of this preparation (approximately 50 ng) had an activity equivalent to about 0.1ml of human serum. This activity is nearly identical when related to the amount of protein. Studies of heat stability demonstrated that the expressed protein was stable to heat treatment (65"C for 20 minutes) whereas human serum under similar treatment showed loss of activity. EXAMPLE 5 - Activity of protein expressed from pNHlδa The expressed protein from pNHlδa (Example 3 - NCIMB 40341) was examined for stability by exposure to heat and to pH changes. Activity was measured as described in Example 4 above. When heated to 60 β C for 30 minutes the protein retained functional activity when compared with alpha-1-antitrypsin (AAT) . The activity was about 30% of untreated sample whereas with AAT there was virtually no activity detectable suggesting that the expressed protein was relatively more thermostable. On exposure to acid pH, the expressed protein was inactivated by pH<4.5 whereas AAT retained approximately 30% of its activity. At pH>9.0 the expressed protein was inactivated. One point of note is the presence of glycosylated residues in AAT which may influence the stability and are not present in the expressed protein. SEQUENCE LISTING; SEQ ID NO: 1 SEQUENCE TYPE: Nucleotide with corresponding amino acid SEQUENCE LENGTH: 1339 base pairs FEATURES: From 1 to 6 bp: BamHI site From 991 to 996 bp: BamHI site PROPERTIES: Human serine protease inhibitor SEQUENCE: GG ATC CTC AGC CAG GGA GAC AGG GAC CAG GCA GCA CAG 38 lie Leu Ser Gin Gly Asp Arg Asp Gin Ala Ala Gin 5 10 GCC TGC CAG CAG GAG GAT GCC CCA CGA GAC AGA AGA 74 Ala Cys Gin Gin Glu Asp Ala Pro Arg Asp Arg Arg 15 20 CGG CAT TGT CGA TTC ACT GTC CCA GGT CAG TGG TGG 110 Arg His Cys Arg Phe Thr Val Pro Gly Gin Trp Trp 25 30 35 TGC CTG AAG CTA GTG GAT AAG TTT TTG GAG GAT GTT 146 Cys Leu Lys Leu Val Asp Lys Phe Leu Glu Asp Val 40 45 AAA AAG TTG TAC CAC TCA GAA GCC TTC ACT GTC AAC 182 Lys Lys Leu Tyr His Ser Glu Ala Phe Thr Val Asn 50 55 60 TTC GGG GAC ACC GAA GAG GCC AAG AAA CAG ATC AAC 218 Phe Gly Asp Thr Glu Glu Ala Lys Lys Gin lie Asn 65 70 GAT TAC GTG GAG AAG GGT ACT CAA GGG AAA ATT GTG 254 Asp Tyr Val Glu Lys Gly Thr Gin Gly Lys lie Val 75 80 GAT TTG GTC AAG GAG CTT GAC AGA GAC ACA GTT TTT 290 Asp Leu Val Lys Glu Leu Asp Arg Asp Thr Val Phe 85 90 95 GCT CTG GTG AAT TAC ATC TTC TTT AAA GGC AAA TGG 326 Ala Leu Val Asn Tyr lie Phe Phe Lys Gly Lys Trp 100 105 GAG AGA CCC TTT GAA GTC AAG GAC ACC GAG GAA GAG 362 Glu Arg Pro Phe Glu Val Lys Asp Thr Glu Glu Glu 110 115 120 GAC TTC CAC GTG GAC CAG GTG ACC ACC GTG AAG GTG 398 Asp Phe His Val Asp Gin Val Thr Thr Val Lys Val 125 130 CCT ATG ATG AAG CGT TTA GGC ATG TTT AAC ATC CAG 434 Pro Met Met Lys Arg Leu Gly Met Phe Asn lie Gin 135 140 CAC TGT AAG AAG CTG TCC AGC TGG GTG CTG CTG ATG 470 His Cys Lys Lys Leu Ser Ser Trp Val Leu Leu Met 145 150 155 AAA TAC CTG GGC AAT GCC ACC GCC ATC TTC TTC CTG 506 Lys Tyr Leu Gly Asn Ala Thr Ala lie Phe Phe Leu 160 165 CCT GAT GAG GGG AAA CTA CAG CAC CTG GAA AAT GAA 542 Pro Asp Glu Gly Lys Leu Gin His Leu Glu Asn Glu 170 175 180 CTC ACC CAC GAT ATC ATC ACC AAG TTC CTG GAA AAT 578 Leu Thr His Asp lie lie Thr Lys Phe Leu Glu Asn 185 190 GAA GAC AGA AGG TCT GCC AGC TTA CAT TTA CCC AAA 614 Glu Asp Arg Arg Ser Ala Ser Leu His Leu Pro Lys 195 200 CTG TCC ATT ACT GGA ACC TAT GAT CTG AAG AGC GTC 650 Leu Ser lie Thr Gly Thr Tyr Asp Leu Lys Ser Val 205 210 215 CTG GGT CAA CTG GGC ATC ACT AAG GTC TTC AGC AAT 686 Leu Gly Gin Leu Gly lie Thr Lys Val Phe Ser Asn 220 225 GGG GCT GAC CTC TCC GGG GTC ACA GAG GAG GCA CCC 722 Gly Ala Asp Leu Ser Gly Val Thr Glu Glu Ala Pro 230 235 CTG AAG CTC TCC AAG GCC GTG CAT AAG GCT GTG CTG 758 Leu Lys Leu Ser Lys Ala Val His Lys Ala Val Leu 240 245 250 ACC ATC GAC GAG AAA GGG ACT GAA GCT GCT GGG GCC 794 Thr lie Asp Glu Lys Gly Thr Glu Ala Ala Gly Ala 255 260 ATG TTT TTA GAG GCC ATA CCC ATG TCT ATC CCC CCC 830 Met Phe Leu Glu Ala lie Pro Met Ser lie Pro Pro 265 270 275 GAG GTC AAG TTC AAC AAA CCC TTT GTC TTC TTA ATG 866 Glu Val Lys Phe Asn Lys Pro Phe Val Phe Leu Met 280 285 ATT GAA CAA AAT ACC AAG TCT CCC CTC ~ TTC ATG GGA 902 lie Glu Gin Asn Thr Lys Ser Pro Leu Phe Met Gly 290 295 AAA GTG GTG AAT CCC ACC CAA AAA TAACTGCCTC 936 Lys Val Val Asn Pro Thr Gin Lys 300 305 TCGCTCCTCA ACCCCTCCCC TCCATCCCTG GCCCCCTCCC 976 TGGATGACAT TAAAGGATCC GCAAGTTTCA TGAGCTAAAA 1016 TATTTAGCAC TATCTACTTT TTTTTTTTCT TTTAAAGGGT 1056 TTTTTAAGAG GGAGAAAAAA ATGCACACAA AGCAGTGAAT 1096 AGTAGGCTAG ACTCATTGGG GGGTAATTAC CCTAGACTCC 1136 TAACTTTCCA GGCTAGTTGA GGAAACTAAG GAATGCCTCC 1176 CAATATTCCA ACCCTCAAAG CTCACACTGC CCCCAGAAAA 1216 ACAAAACACT CACCCCCAAT CCAATGAATC ATCTGCATAG 1256 AAAACCAGAG CCAGCAGGCC TAGGGAAGGA GCGGATGTGT 1296 GTTGCCCTCC TCTACAACAT ACCACTGAAC TAGTATGTGC 1336 TAG 1339 **** END OF SEQUENCE LISTING ***

Claims: CLAIMS 1. A human serine protease inhibitor whose unglyσosylated molecular weight is 32 kDa + 1 kDa. 2. A proteinaceous molecule selected from: a) a molecule having the amino acid sequence shown in SEQ ID NO:l or a sequence not differing substantially therefrom; b) a polypeptide having substantially the same structure and biological activity as a) ; and c) fragments , derivatives and mutants of a) or b) significantly involved in their biological activity. 3 . A proteinaceous molecule selected from: a) a polypeptide hav ing serine protea s e inhibitor activity and whose amino terminus includes the sequence of amino acids 1 to 37 of SEQ ID NO : 1 or a sequence not dif fering substantially therefrom; b) a polypeptide having substantially the same structure and biological activity as a) ; c) fragments , derivatives and mutants of a) or b) significantly involved in their biological activity. 4. A proteinaceous molecule as claimed in claim 2 or 3, wherein the derivative is a glycosylated derivative. 5. A process for the preparation of a proteinaceous molecule as claimed in claim 2 or 3, the process comprising coupling together successive amino acid residues and/or ligating oligo- and/or poiypeptides. 6. Recombinant or isolated DNA encoding a proteinaceous molecule as claimed in claim 1 , 2 or 3. 7. DNA as claimed in claim 6 encoding the amino acid sequence shown in SEQ ID NO:l. 8. DNA as claimed in claim 6 having the nucleotide sequence shown in SEQ ID NO:l. 9. Recombinant or isolated DNA which hybridises to DNA as claimed in claim 6, 7 or 8. 10. DNA as claimed in claim 6, 7 or 8 which is in the form of a vector. 11. A vector as claimed in claim 10 which is an expression vector including an operatively linked promoter. 12. A host cell transfected or transformed with a vector as claimed in claim 10 or 11. 13. A host cell as claimed in claim 12, which is Escherichia coli. 14. A host cell as claimed in claim 12, which is a mammalian cell. 15. A process for preparing DNA as claimed in claim 6, 7 or 8, the process comprising coupling together successive nucleotides, and/or ligating oligo- and/or poly-nucleotides. 16. A proteinaceous molecule as claimed in any one of claims 1 to 4 for use in medicine. 17. The use of a proteinaceous compound as claimed in any one of claims 1 to 4 in the manufacture of a medicament for the treatment or prophylaxis of emphysema, arthritis or septic shock. 18. A method for the treatment or prophylaxis of emphysema, arthritis or septic shock, the method comprising administering to a patient an effective, generally non-toxic, amount of a proteinaceous compound as claimed in any one of claims 1 to 4. 19. A pharmaceutical formulation comprising a proteinaceous compound as claimed in any one of claims 1 to 4 and a pharmaceutically acceptable carrier therefor. 20 An antibody capable of specifically binding a proteinaceous compound as claimed in any one of claims 1 to 4.

Inventors: KALSHEKER NOOR AHMED, KALSHEKER, NOOR, AHMED
Applicants: 3I RES EXPL LTD, 3I RESEARCH EXPLOITATION LIMITED
Application year: 1990
Main classification: C12N15
IPC codes: A61K38, A61K39, A61P11, A61P29, C07K14, C07K19, C12N1, C12N5, C12N9, C12N15, C12P21, C12R1